Adjuvant immunotherapy for melanoma patients: progress and opportunities.
Adjuvant immunotherapy for melanoma patients: progress and opportunities.
复制标题
黑色素瘤患者的辅助免疫治疗：进展和机遇。
DOI：
10.1016/j.esmoop.2024.102962
复制
发表时间：
2024
期刊：
影响因子：
7.3
通讯作者：
Ott,PA
中科院分区：
文献类型：
--
作者：
Sussman,TA;Ott,PA
亮点高危黑色素瘤患者的免疫治疗环境迅速复杂化。新辅助免疫治疗在可手术切除的高危黑色素瘤患者中发挥着越来越重要的作用。确定辅助治疗中最有效的治疗方案将需要额外的随机研究。新型检查点抑制剂、个性化疫苗和更好的预测工具即将出现。大多数被诊断为皮肤黑色素瘤的患者都是手术切除的候选者，因此他们的疾病是可以治愈的。然而，对于许多患者来说，复发的风险很高，包括淋巴结阴性黑色素瘤患者，因此需要手术以外的其他治疗。随着基于抗程序性细胞死亡蛋白 1 (PD-1) 的免疫疗法的出现，与之前在晚期环境中的标准护理治疗相比，这种疗法要有效得多，辅助治疗的格局近年来发生了根本性的变化。基于抗 PD-1 的免疫检查点抑制疗法现已成为许多 IIB 期或更高级别黑色素瘤患者的标准治疗方法。与单独辅助治疗相比，新辅助治疗已显示出更好的结果。然而，仍然存在许多问题，包括治疗组合（例如联合抗 PD-1+ 淋巴细胞激活基因 3）、最佳治疗顺序以及使用预测标记来进一步改善高危黑色素瘤患者的预后。
HighlightsThe immunotherapeutic treatment landscape for patients with high-risk melanoma has increased in complexity at a rapid pace.Neoadjuvant immunotherapy has an increasingly important role in patients with high-risk surgically resectable melanoma.Identifying the most effective therapeutic regimen in the adjuvant setting will require additional randomized studies.Novel checkpoint inhibitors, personalized vaccines, and better predictive tools are on the horizon.The majority of patients who are diagnosed with cutaneous melanoma are candidates for surgical resection and thus curable from their disease. However, the risk for a recurrence is high for many patients, including those with lymph node-negative melanoma, thus necessitating additional therapies beyond surgery. With the advent of anti-programmed cell death protein 1 (PD-1)-based immunotherapies, which are vastly more effective compared to previous standard-of-care treatments in the advanced setting, the landscape of adjuvant therapy has fundamentally changed in recent years. Anti-PD-1-based immune checkpoint inhibition therapy is now the standard of care for many patients with stage IIB or higher melanoma. Neoadjuvant approaches have demonstrated superior outcomes compared to adjuvant-alone therapy. However, a number of questions remain including treatment combinations such as combined anti-PD-1+ lymphocyte activation gene-3, optimal sequencing of therapies, and the use of predictive markers to further improve outcomes for patients with high-risk melanoma.
影响因子：
20.3
作者：
Placke, Theresa;Faber, Katrin;Froehling, Stefan
通讯作者：
Froehling, Stefan